Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) receives ‘RECCE’ trademark from the Trade Marks Registry Intellectual Property Department in Hong Kong
- It bolsters the company’s IP portfolio, with issued patents and patent applications already in the biggest pharmaceutical markets in the world
- The pharmaceutical market in Hong Kong is valued at US$2.3 billion (A$3.2 billion)
- Recce believes its anti-infectives have the potential to overcome the “hypercellular mutation of bacteria and viruses”
- Shares in RCE last traded at 64 cents at market close
Recce Pharmaceuticals (RCE) has been granted a trademark for ‘RECCE’ from the Trade Marks Registry Intellectual Property Department in Hong Kong.
The trademark bolsters the company’s intellectual property (IP) portfolio, with issued patents and patent applications already in the world’s biggest pharmaceutical markets, Australia, the US, Europe, Japan and China.
The company was issued Hong Kong Trademark No. 306020153 for RECCE and is classified under ‘Class 5’ – antibiotics, antibiotics for human use and pharmaceutical preparations, namely mixed antibiotic preparations.
Recce Pharmaceuticals CEO James Graham said it was pleasing to secure the trademark in Hong Kong.
“With patents in Hong Kong for RECCE® anti-infectives in place to 2037, we now celebrate further exclusivity through the trademark registration of RECCE,” he said.
The pharmaceutical market in Hong Kong is valued at US$2.3 billion (A$3.2 billion), with an increasingly greater demand for chronic disease treatment.
The company’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives.
‘RECCE 327’ is an intravenous and topical therapy being developed to treat serious and life-threatening infections due to gram-positive and gram-negative bacteria.
‘RECCE 435’ is an orally administered therapy for bacterial infections; and ‘RECCE 529’ treats viral infections.
Recce said data from the Hospital Authority of Hong Kong revealed a proportionally high level of anti-microbial resistance in both gram-positive and gram-negative bacteria in Hong Kong relative to other countries.
The company believes its anti-infectives have the potential to overcome the hyper-cellular mutation of bacteria and viruses, which has always been the challenge of existing antibiotics to date.
Shares in RCE last traded at 64 cents at market close.
